Huons Meditech, a subsidiary of the Huons Group specializing in medical devices, announced on December 27th that its flagship "DermaShine" drug delivery system has exceeded cumulative sales of 20,000 units since its launch.

Since its introduction in 2011, the DermaShine series has evolved with upgraded models such as the DermaShine Balance and DermaShine Pro, establishing a dominant position in the drug delivery system market. Domestic sales have reached over 7,000 units, primarily catering to dermatology clinics, plastic surgery centers, and private practices. Meanwhile, international sales—led by China and Southeast Asia—account for more than 13,000 units, solidifying DermaShine's status as a global leader in its segment.

The DermaShine series employs an automated, input-sensitive injection system designed to deliver high-molecular, high-concentration hyaluronic acid such as Elravie Balance, renowned for its moisturizing properties and credited with driving South Korea's "glass skin" trend. To address evolving market demands, the company introduced a premium needle last year to reduce pain and fluid leakage during treatments.

With the expanding market for high-molecular skin boosters like PDLA (Poly D-Lactic Acid) and PLLA (Poly L-Lactic Acid), along with a diverse range of related products, demand continues to grow for advanced drug delivery systems. To meet these needs, Huons Meditech plans to launch the DermaShine Duo RF in the first half of 2025. This innovation combines drug delivery with RF (radiofrequency) treatment, aiming to enhance comfort and minimize fluid leakage during skin booster injections.

CEO Jin-Seok Lee emphasized the company's commitment to innovation, stating:

"We are fully committed to developing aesthetic medical devices optimized to meet market needs, focusing on differentiation and cost-effectiveness. Through continuous research and development, we aim to strengthen our presence in international markets and solidify our position as a global medical device company."